Skip to main content
Industry News
FDA guidance targets adverse event reporting during trials
5/20/2020

The FDA has updated its guidance for adverse event reporting in clinical trials conducted during the COVID-19 pandemic. For example, in trials of approved drugs being studied for COVID-19, companies must report spontaneous reports of serious adverse events related to the drug's off-label use in clinical practice to treat COVID-19.

Full Story: